Singapore, Feb. 3 -- South Korea-based SK bioscience will advance a novel respiratory syncytial virus (RSV) monoclonal antibody (mAb) for global health under license from the Gates Medical Research Institute (Gates MRI).SK bioscience has entered into a license agreement with Gates MRI, a nonprofit medical research organization, an affiliate of the Gates Foundation, to develop and commercialise a clinical-stage monoclonal antibody candidate prophylactic treatment for the prevention of RSV infection.

The RSV preventive mAb candidate, engineered by Adimab in collaboration with Gates MRI is designed to be administered to newborns and infants born during or entering their first RSV season, with a single dose intended to provide rapid and dura...